Hear from Akash Bakshi, CEO of Your Choice Therapeutics and now Ana Therapeutics on how he pivoted his Y Combinator-backed startup focussed on developing a male birth control pill to test a COVID-19 treatment. On the 4th of August, the FDA announced that it has cleared the investigational new drug (IND) application for ANA001 (Niclosamide Capsules) as a potential treatment for COVID-19, making it the first U.S.-based company to conduct a human clinical trial to determine the efficacy of Niclosamide to treat COVID-19.
Add comment